Conning Inc. Grows Stake in Abbott Laboratories $ABT

Conning Inc. grew its stake in Abbott Laboratories (NYSE:ABT) by 8.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 274,468 shares of the healthcare product maker’s stock after purchasing an additional 21,178 shares during the period. Abbott Laboratories makes up about 1.2% of Conning Inc.’s portfolio, making the stock its 18th biggest position. Conning Inc.’s holdings in Abbott Laboratories were worth $34,388,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of ABT. Brighton Jones LLC grew its holdings in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the last quarter. United Bank boosted its position in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares during the period. Main Street Financial Solutions LLC grew its stake in shares of Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after buying an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its holdings in shares of Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after buying an additional 292,547 shares during the period. Institutional investors own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: TipRanks highlighted Abbott as one of three “Strong Buy” Dividend Aristocrat stocks, which can support the stock’s appeal for income-focused investors despite a high payout ratio. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26
• Neutral Sentiment: Jim Cramer called Abbott one of the “greatest American companies” while comparing the selloff to the 1999 market backdrop, a comment that may help sentiment but does not change fundamentals. Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment
• Neutral Sentiment: Recent insider-trading coverage noted buying activity around Abbott, which can be viewed as a modest confidence signal but is not necessarily a major catalyst on its own. Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell (ABT)
• Negative Sentiment: Investor concerns remain centered on Abbott’s post-earnings weakness, with commentary pointing to Exact Sciences dilution, legal risks, and softer Diagnostics trends as reasons the shares have been pressured. Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?

Insider Buying and Selling

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares in the company, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,055 shares of company stock valued at $353,097 over the last three months. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of recent analyst reports. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Argus reduced their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Benchmark lowered their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Stifel Nicolaus dropped their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Evercore decreased their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $119.43.

Abbott Laboratories Trading Up 1.2%

NYSE ABT opened at $84.80 on Friday. The company’s 50-day simple moving average is $99.59 and its two-hundred day simple moving average is $113.55. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The company has a market capitalization of $147.70 billion, a price-to-earnings ratio of 23.75, a price-to-earnings-growth ratio of 1.40 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.